UroCor to distribute radiation seed implants:
This article was originally published in Clinica
Executive Summary
UroCor has signed an exclusive five-year marketing agreement with Mills Biopharmaceuticals for its Iodine 125 radiation seed implants for use in brachytherapy. Under the agreement, the two companies will share revenues resulting from Oklahoma City-based UroCor's direct sales in the US and from any other distribution agreements it forms. Mills has filed for approval in the US for the product. Iodine 125 seeds are used to treat prostate cancer, which affects about 200,000 men annually.